Abstract:The heterogeneity of Hepatocellular Carcinoma (HCC) poses a barrier to effective treatment. Stratifying highly heterogeneous HCC into molecular subtypes with similar features is crucial for personalized anti-tumor therapies. Although driver genes play pivotal roles in cancer progression, their potential in HCC subtyping has been largely overlooked. This study aims to utilize driver genes to construct HCC subtype models and unravel their molecular mechanisms. Utilizing a novel computational framework, we expanded the initially identified 96 driver genes to 1192 based on mutational aspects and an additional 233 considering driver dysregulation. These genes were subsequently employed as stratification markers for further analyses. A novel multi-omics subtype classification algorithm was developed, leveraging mutation and expression data of the identified stratification genes. This algorithm successfully categorized HCC into two distinct subtypes, CLASS A and CLASS B, demonstrating significant differences in survival outcomes. Integrating multi-omics and single-cell data unveiled substantial distinctions between these subtypes regarding transcriptomics, mutations, copy number variations, and epigenomics. Moreover, our prognostic model exhibited excellent predictive performance in training and external validation cohorts. Finally, a 10-gene classification model for these subtypes identified TTK as a promising therapeutic target with robust classification capabilities. This comprehensive study provides a novel perspective on HCC stratification, offering crucial insights for a deeper understanding of its pathogenesis and the development of promising treatment strategies. Dividing highly heterogeneous HCC into molecular subtypes with similar characteristics is crucial for personalized anti-tumor therapies. Although driver genes play pivotal roles in cancer progression, their potential in HCC subtyping has been largely overlooked. In this work, we developed a multi-omics network-based stratification algorithm that utilizes patient mutation data and requires smaller computational resources for subtype assignment. Through this algorithm, we categorized HCC into two subtypes, CLASS A and CLASS B. Using multi-omics and single-cell data, we identified differences between these subtypes in gene expression, methylation, immune infiltration, and other aspects. Beyond subtype characterization, our study established a robust clinical prediction model (https://mike-wang-bjut.shinyapps.io/DynNomapp_HCC_Sutypes/) incorporating subtype information and typical clinical features, enabling precise survival predictions. Finally, we developed a high-performing machine learning classifier for our subtype. Analyzing this classification model and reviewing previous experimental papers, we identified TTK as a potential diagnostic marker and therapeutic target specific to our subtypes. In conclusion, our research offers a novel perspective on HCC stratification, which is crucial for a deeper understanding of its pathogenesis and developing promising treatment strategies.

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma

A novel molecular subtype of hepatocellular carcinoma based on the tumor purity and tumor microenvironment-related polygenic risk scores.

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses

Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment

Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy

Integrated Multiomic Analysis Reveals Comprehensive Tumour Heterogeneity and Novel Immunophenotypic Classification in Hepatocellular Carcinomas

Integrated Multi-Omic Analysis To Reveal Comprehensive Tumor Heterogeneity And Novel Immunophenotypic Classification In Primary Liver Cancer.

Immune-Metabolic-Based Subtyping Decodes Tumour Heterogeneity and Reveals a Potential Therapeutic Strategy for Hepatocellular Carcinoma

Microenvironment Characterization and Multi-Omics Signatures Related to Prognosis and Immunotherapy Response of Hepatocellular Carcinoma

Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis

A Novel Molecular Classification System Based on the Molecular Feature Score Identifies Patients Sensitive to Immune Therapy and Target Therapy

Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma

Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma

Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response

Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma

Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions